Are there antibody-drug conjugates approved for Waldenstrom Macroglobulinemia

Antibody-Drug Conjugates for Waldenstrom Macroglobulinemia

Based on the current NCCN Guidelines for Waldenstrom Macroglobulinemia (Version 3.2025), there are no antibody-drug conjugates (ADCs) listed as approved or recommended treatment options for WM in the primary or relapsed/refractory treatment algorithms.

What the Guidelines Show

The NCCN Guidelines outline several preferred and recommended treatment approaches for WM:

Preferred primary treatments include:

• Bendamustine and rituximab
• Ibrutinib (a BTK inhibitor)
• Ibrutinib and rituximab
• Zanubrutinib (another BTK inhibitor)

Other recommended options include:

• Bortezomib, rituximab, and dexamethasone
• Carfilzomib, rituximab, and dexamethasone
• Ixazomib, rituximab, and dexamethasone

None of these are antibody-drug conjugates. Instead, WM treatment focuses on:

• Monoclonal antibodies (like rituximab, which targets CD20)
• BTK inhibitors (targeted therapies that block specific cancer cell pathways)
• Proteasome inhibitors (like bortezomib and carfilzomib)
• Chemotherapy (bendamustine, cyclophosphamide)

Why This Matters

ADCs are a newer class of cancer drugs that combine antibodies with chemotherapy payloads. While they've been approved for some other lymphomas and blood cancers, they haven't yet been incorporated into WM treatment guidelines.

Questions to Ask Your Oncologist

1. Are there any clinical trials available for ADCs or other newer therapies for WM?
2. Which of the recommended treatments do you think is best for my specific situation?
3. Are there any emerging therapies on the horizon for WM?

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.